Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 5:03 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 7,258 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: High-Risk Clear all

Conditions: Myelodysplastic Syndrome
Interventions: pracinostat, Placebo, Azacitidine; Drug
Lead sponsor: Helsinn Healthcare SA; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 24
States / cities: Mobile, Alabama • La Jolla, California • Denver, Colorado + 21 more

Conditions: Post Operative Surgical Site Infection
Interventions: Supplemental Perioperative Oxygen; Procedure
Lead sponsor: Major Extremity Trauma Research Consortium; Other
Eligibility: 18 Years to 80 Years
Enrollment: 1,171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 2
States / cities: Phoenix, Arizona • Baltimore, Maryland

Conditions: Actinic Keratosis
Interventions: Aminolevulinic Acid, Topical Solution Vehicle, BLU-U, Cryotherapy; Drug · Device · Procedure
Lead sponsor: DUSA Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 8
States / cities: San Diego, California • Arlington Heights, Illinois • Carmel, Indiana + 4 more

Conditions: Acute Myeloid Leukemia, Acute Undifferentiated Leukemia, Mixed Phenotype Acute Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Acute Undifferentiated Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Acute Undifferentiated Leukemia, Refractory Chronic Myelomonocytic Leukemia, Refractory Mixed Phenotype Acute Leukemia, Refractory Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia
Interventions: Decitabine, Bone Marrow Aspiration, Bone Marrow Biopsy, Chest Radiography, Cytarabine, Echocardiography Test, Filgrastim, Fludarabine, Hematopoietic Cell Transplantation, Idarubicin, Multigated Acquisition Scan, Pheresis, Total-Body Irradiation, Biospecimen Collection; Drug · Procedure · Biological + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM), Autologous Stem Cell Transplant
Interventions: Isatuximab, Lenalidomide, Bortezomib Injection, Dexamethasone; Drug
Lead sponsor: Jacob Laubach, MD; Other
Eligibility: 75 Years and older
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Recurrent Diffuse Large B-Cell Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma
Interventions: Busulfan, Gemcitabine, Melphalan, Olaparib, Peripheral Blood Stem Cell Transplantation, Pharmacokinetic Study, Rituximab, Vorinostat; Drug · Procedure · Other + 1 more
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: High-grade Gliomas (HGG)
Interventions: Dexamethasone, Azeliragon; Drug
Lead sponsor: Akshitkumar MIstry; Other
Eligibility: 19 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Louisville, Kentucky

Conditions: Mitral Valve Insufficiency
Interventions: Half Moon TMVr System; Device
Lead sponsor: Half Moon Medical; Industry
Eligibility: 21 Years to 95 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 5
States / cities: New York, New York • The Bronx, New York • Cleveland, Ohio + 2 more

Conditions: Anxiety Disorder, Chronic Myeloproliferative Disorders, Depression, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Pain
Interventions: pain therapy, psychosocial assessment and care; Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2003
U.S. locations: 1
States / cities: New York, New York

Conditions: Endothelial Dysfunction
Interventions: Creatine Monohydrate, Maltodextrin (Placebo); Other
Lead sponsor: Florida State University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Tallahassee, Florida

Conditions: Obesity
Interventions: Dietary Compliance; Behavioral
Lead sponsor: Rippe Lifestyle Institute; Industry
Eligibility: 20 Years to 60 Years
Enrollment: 366 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Celebration, Florida

Conditions: Clinical High Risk for Psychosis
Interventions: Pomaglumetad methionil; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 30 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer
Interventions: Palbociclib, Fulvestrant, Adjuvant Therapy; Drug
Lead sponsor: Criterium, Inc.; Industry
Eligibility: Not listed
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 19
States / cities: Tucson, Arizona • Los Angeles, California • Aurora, Colorado + 15 more

Conditions: Influenza
Interventions: High Dose Inactivated Influenza Vaccine, Standard Dose Inactivated Influenza Vaccine; Biological
Lead sponsor: University of Pittsburgh; Other
Eligibility: 65 Years and older
Enrollment: 205 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Prostate Cancer
Interventions: External beam radiation therapy, Prostate brachytherapy boost, Androgen deprivation therapy, Positron emission tomography (PET)/magnetic resonance imaging (MRI); Radiation · Drug · Diagnostic Test
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Acquired Immunodeficiency Syndrome, Kaposi's Sarcoma, Leukemia, Lymphoma, Tumor Virus Infection, HIV Infections
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Lung Cancer Stage II, Lung Cancer Stage III, Non Small Cell Lung Cancer
Interventions: SBRT, Carboplatin, Paclitaxel, cis Platinum, Etoposide, IMRT, Durvalumab; Radiation · Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Weight Reduction, Obesity, Weight Management
Interventions: Herbalife Meal Replacements; Dietary Supplement
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 30 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Various Advanced Cancer
Interventions: Nivolumab, Ipilimumab; Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 6 Months to 21 Years
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 14
States / cities: Los Angeles, California • Aurora, Colorado • Gainesville, Florida + 10 more

Conditions: Salivary Gland Malignancy
Interventions: Postoperative Radiotherapy and Panitumumab; Drug
Lead sponsor: Athanassios Argiris; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Prostatic Neoplasms, Bone Mineral Density Quantitative Trait Locus 3
Interventions: vitamin D, Placebo; Dietary Supplement
Lead sponsor: University of Rochester; Other
Eligibility: 60 Years to 99 Years · Male only
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Carcinoma, Non-small Cell Lung
Interventions: Carboplatin, Nab-paclitaxel; Drug
Lead sponsor: Yale University; Other
Eligibility: 71 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy
Interventions: Tirzepatide; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Neuroblastoma
Interventions: β-glucan, GM-CSF, OPT-821; Dietary Supplement · Drug · Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 286 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Phase 2 Study of Pracinostat With Azacitidine in Patients With Previously Untreated Myelodysplastic Syndrome

Supplemental Perioperative Oxygen to Reduce Surgical Site Infection After High Energy Fracture Surgery

Controlled Study of the Occurrence of Actinic Keratosis on the Face After Cryotherapy + Aminolevulinic Acid (ALA) Photodynamic Therapy

Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse

Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM

Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant

Steroid Avoidance, Dexamethasone, and RAGE Inhibition for Perioperative Cerebral Edema Management in High-Grade Gliomas

The Half Moon Transcatheter Mitral Valve Repair (TMVr) Pilot Study

Music Therapy to Ease Pain and Emotional Distress in Patients With Hematologic Cancer Who Are Undergoing High-Dose Therapy and Stem Cell Transplantation

The Effect of NADPH Oxidase and Creatine Supplementation on Microvascular Blood Flow Regulation

A Comparison of the Metabolic Effects of Fructose, Glucose, High Fructose Corn Syrup and Sucrose at Normal Population Consumed Levels in Adults Aged 20-60 Years Old

Glutamate Reducing Interventions in Schizophrenia

DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)

Randomized Trial of High Dose Influenza Vaccine in Long Term Care Setting

Imaging and Genomic Biomarkers to Predict Response in Prostate Cancer

Clinical, Laboratory and Epidemiologic Pilot Studies of Individuals at High Risk for Viral-Associated Cancers

Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC

Effects of Protein-Enriched Meal on Liver, Kidney or Bone: a Randomized Controlled Trial

A Study to Evaluate the Safety and Efficacy of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Participants With High Grade Primary Central Nervous System (CNS) Malignancies

Postoperative Radiotherapy and Panitumumab in High-Risk Salivary Gland Malignancies

High-dose Vitamin D Supplementation for ADT-induced Side Effects

Single Agent Versus Combination Chemotherapy to Treat High-risk Elderly With Non-small Cell Lung Cancer

A Study of Tirzepatide at Different Injection Sites in Participants With Different Body Sizes

A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma